Modified stem cells used to produce missing blood clotting factors
Engineered allogeneic stem cells, which were shielded from the immune system by biomaterial encapsulation, have been used to treat hemophilia by producing recombinant human hemophilia factors.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>